Another novel highly potent selective 4th-generation EGFR TKI BLU-945 also has promising activity for the treatment of EGFR T790M/C797S resistant NSCLC, with high selectivity, and the ongoing SYMPHONY will reveal more data (86). Here, EGFR is linked to non-small cell lung carcinoma.